Company intelligence / Profile preview

Eutropics

Cambridge, Massachusetts, United Stateseutropics.com ↗

Ownership: Private
Development stage: Commercial

Overview

Eutropics provides CLIA-certified functional diagnostic tests that guide cancer treatment decisions by profiling tumor susceptibility to therapies. Their PraediCare Dx™ platform has demonstrated medical utility in blood cancers such as AML and CLL. The company’s technology enables personalized medicine by identifying patients most likely to respond to specific treatments.

Therapeutic areas: OncologyHematology
Modalities: Diagnostic assay
Industry: Protein Biomarker Diagnostics

Partnerships

Collaborations with pharmaceutical companies and leading academic cancer centers in the U.S., U.K., and Canada

Beyond the preview

Go deeper on Eutropics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eutropics.

Explore the full profile